ASCO 2021: Summary Overview and Outlook 5 Dana-Farber Cancer Institute ASCO Key Research Focus

For followers of the academic progress of oncology, the release of the Asco summary is one of the biggest events of the year.

For followers of the academic progress of oncology, the release of the Asco summary is one of the biggest events of the year.

Part 1 Reference: ASCO 2021: Summary Overview and Outlook 4 Part 1 Reference: ASCO 2021: Summary Overview and Outlook 4 Part 1 Reference: ASCO 2021: Summary Overview and Outlook 4

This episode brings you the latest research results and previews of Dana-Farber Cancer Institute~

This episode brings you the latest research results and forecasts of Dana-Farber Cancer Institute~ This episode brings you the latest research results and forecasts of Dana-Farber Cancer Institute~

Researchers from the Dana-Farber Cancer Institute (Dana-Farber Cancer Institute), a cancer specialist affiliated to Harvard Medical School in the United States , submitted dozens of research results at the 2021 American Society of Clinical Oncology ( ASCO ) annual meeting.

ASCO

Toni K.

Dana-Farber Cancer Institute Melanoma Center and Director of the Immuno- oncology Center, Dr.

immunity

Other key studies have shown advances in new therapies and diagnosis in lung cancer, leukemia, head and neck cancer, pediatrics and many other diseases .

Other key studies have shown advances in new therapies and diagnosis in lung cancer, leukemia, head and neck cancer, pediatrics and many other diseases .

Antibody-drug conjugates are expected to target the treatment of non-small cell lung cancer

Antibody-drug conjugates are expected to be anti-non-small cell lung cancer targeted therapy Antibody drug conjugates are expected to be anti-non-small-cell lung cancer targeted therapy

Antibodies fused with targeted drugs have produced impressive results in a phase I clinical trial involving patients with advanced non-small cell lung cancer ( NSCLC ) whose tumors have already developed against standard targeted therapies Resistance.

NSCLC

The trial evaluated Patruma Drutecan (an antibody-drug conjugate composed of an antibody targeting the protein HER3 and an inhibitor of the topoisomerase 1 enzyme) in 57 cases of NSCLC with EGFR gene mutations but Safety and effectiveness in patients who no longer respond to EGFR targeting.

After a median treatment time of 5.

After a median treatment time of 5.

The most common serious side effects are lower platelet counts, lower neutrophil (a type of white blood cell) count, and fatigue-all of which are consistent with previous safety studies.

Highlights of Dana-Farber Cancer Institute:

Topic: Efficacy and safety of Patrick Drutecan (HER3-DXd) in non-small cell lung cancer (NSCLC) resistant to EGFR inhibitor resistance and EGFR mutations (EGFRm)

Topic: Efficacy and safety of Patrick Drutecan (HER3-DXd) in non-small cell lung cancer (NSCLC) resistant to EGFR inhibitor resistance and EGFR mutations (EGFRm)

Summary: 9007

Speaker: Pasi A.

Conference/Time: Oral Abstract Conference: Lung Cancer-Non-Small Cell Metastasis; Live Broadcast: June 4, 1:00pm-4:00pm

PET scans after initial treatment can help many patients with large early Hodgkin's lymphoma avoid radiotherapy

PET scans after initial treatment can help many patients with large early-stage Hodgkin's lymphoma avoid radiotherapy for lymphoma

According to a clinical study of treatment based on PET imaging findings, many early patients with large classical Hodgkin lymphoma (cHL) can avoid radiotherapy and still have excellent therapeutic effects.

Breast cancer

The results presented by Ann LaCasce of MMSc, ​​MD, Dana-Farber Cancer Institute included 94 patients with IA-IIB cHL staging and chest X-ray examination with a disease volume greater than 10 cm or the largest intrathoracic diameter.

The estimated progression-free survival (PFS) was 93.

The researchers said that the use of PET has achieved good PFS results, "this allows 78% of patients to omit radiation therapy.
" PET2 + patients receiving BEACOPP and radiotherapy "have no poor prognosis.
"

Topic: CALGB 50801 (Alliance): PET adapted therapy for large stage I/II classic Hodgkin lymphoma (cHL)

Topic: CALGB 50801 (Alliance): PET adapted therapy for large stage I/II classic Hodgkin lymphoma (cHL)

Abstract: 7507

Speaker: Ann S.
LaCasce, MD, MMSc

Conference/Time: Oral Abstract Conference: Hematological Malignancies-Lymphoma and Chronic Lymphocytic Leukemia ; Live Broadcast: June 7, 11:30 am-2:30pm

Meeting/Time: Oral Abstract Meeting: Hematological Malignancies-Lymphoma and Chronic Lymphocytic Leukemia

Increasing the cycle of pembrolizumab before surgery can improve the remission rate of locally advanced head and neck cancer

Increasing the cycle of pembrolizumab before surgery can improve the remission rate of locally advanced head and neck cancer.
Increasing the cycle of pembrolizumab before surgery can improve the remission rate of locally advanced head and neck cancer.

Dr.
Dana-Farber/Brigham and Dr.
Ravindra Uppaluri of the Women’s Cancer Center reported that increasing neoadjuvant pembrolizumab from one cycle to two cycles before surgery can improve resectable locally advanced, HPV-negative head and neck The pathological response rate of patients with squamous cell carcinoma.
.
A previous study (a total of 36 patients) received a new cycle of pembrolizumab and received surgery two to three weeks later, and its pathological response rate was 22%, >50% (the evidence of tumor cell death and other reactions is called pTR-2).
The pTR-1 rate is 22% (pathological response is 10-49%).
The new report involves a 28-patient Phase 2 clinical trial in which the patients received two cycles of pembrolizumab treatment 42 days and 21 days before surgery.
Of the 28 patients, 12 (43%) experienced pTR-2, and 4 of them (16%) had major pathological reactions, including 1 complete reaction at the primary site.

The neoadjuvant therapy is well tolerated, and the clinical effect is very good in this advanced disease population.
So far, only one relapse has been found.
The researchers said these data indicate that by increasing the number of cycles and treatment intervals, the frequency of pathological responses to neoadjuvant pembrolizumab can be improved.

Topic: In surgically resectable locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC), two cycles of the new cycle of pembrolizumab can enhance the pathological tumor response

Topic: In surgically resectable locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC), two cycles of the new cycle of pembrolizumab can enhance the pathological tumor response

Abstract: 6008

Speaker: Ravindra Uppaluri, MD

Meeting/Time: Oral Summary Meeting: Head and Neck Cancer; Live Broadcast: June 7th, 2:45-5:45 pm

Studies have shown that molecular profiling of tumor tissue can benefit many young cancer patients

Research has shown that molecular profiling of tumor tissue can benefit many young cancer patients.
Research has shown that molecular profiling of tumor tissue can benefit many young cancer patients.

Testing for genetic variants in solid tumors can be targeted by drugs, revolutionizing the treatment of many adult cancers.
A new study conducted by scientists at the Dana-Farber/Boston Children’s Cancer and Blood Disease Center shows that it also has significant benefits for many young patients.

child

Alanna J.
Church, MD, Dana-Farber/Boston Children's Cancer and Blood Disease Center, will present the results of the GAIN/iCat2 Consortium study, which is evaluating the use of genomic profiles of solid tumors in children and young adults.
The report contains data on 345 molecular analysis study participants who were diagnosed with solid non-brain tumors 30 years of age or younger.
299 patients (87%) have at least one genomic change that may be affected.

For more information about Dana-Farber Cancer Institute ASCO 2021 abstract information, please refer to: Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute (Dana-Farber Cancer Institute) was established in 1947.
It is a cancer specialist affiliated hospital of Harvard Medical School, a comprehensive cancer treatment center and AIDS research center designated by the US federal government.
It is also a Dana-Farber Cancer Institute.
One of the founding members of Bo/Harvard Cancer Center, has produced a Nobel Prize winner in medicine.

Since its establishment, it has been providing cancer patients with advanced research to improve their understanding, diagnosis, treatment and prevention of cancer and related diseases .
Dana-Farber Cancer Institute is in the world of cancer gene targeting therapy, cancer immunotherapy, cancer endocrine therapy, cancer biotherapy, cancer vaccines and other clinical aspects.
The treatment advantages of adult tumors are nationwide; the treatment of childhood tumors is ranked in the United States over the years.

Prevent

leaving a message here